Revolution Medicines posts $198M in third-quarter revenue
The revenue figure offers a read on commercial traction for the targeted cancer therapy developer.
Read at Pluang →Full coverage · 6 outlets
- Pluang · lead
- Seeking AlphaRevolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It (RVMD)
- Stock TitanAugust's RASONQUE launch brings Revolution Medicines (RVMD) product sales as Q3 losses widen.
- GenomeWebRevolution Medicines Reports Nearly $198M in Rasonque Sales After Five Weeks on US Market
- BioSpaceRevMed’s Rasonque shatters analyst estimates with $198M quarter
- SeekingalphaRevolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It